{"filing":{"accession_number":"0001193125-26-336864","cik":"0001595097","ticker":"CRBP","company_name":"Corbus Pharmaceuticals Holdings, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"crbp-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526336864/crbp-20260806.htm"},"events":[{"id":25567,"run_id":23206,"accession_number":"0001193125-26-336864","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Corbus Pharmaceuticals reported Q2 2026 financial results for the quarter ended June 30, 2026, including a net loss of $35.0 million (compared to $17.7 million in Q2 2025), operating expenses of $36.2 million, and a cash position of $117.9 million. The press release furnished as Exhibit 99.1 presents condensed consolidated financial statements and operating metrics for the three and six months ended June 30, 2026.","company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26438,"accession_number":"0001193125-26-336864","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Q2 2026 financial results for the quarter ended June 30, 2026, including net loss of $35.0 million (vs. $17.7 million in Q2 2025), operating expenses of $36.2 million, and cash position of $117.9 million. The press release attached as Exhibit 99.1 presents quarterly financial statements and operating metrics, which is the hallmark of an earnings release under Item 2.02. While the release also includes corporate updates on clinical programs and executive appointments, the primary disclosure is the quarterly financial results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:55:54.506485+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26439,"accession_number":"0001193125-26-336864","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure explicitly references \"Item 2.02 Results of Operations and Financial Condition\" and furnishes Exhibit 99.1, which is a press release titled \"Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update.\" The exhibit contains detailed financial statements (condensed consolidated statements of operations and balance sheets) for the three and six months ended June 30, 2026, showing net loss of $35.0 million for Q2 2026 versus $17.7 million in Q2 2025, along with operating expense details and cash position. This is a standard earnings release disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:55:54.506485+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26438,"accession_number":"0001193125-26-336864","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Q2 2026 financial results for the quarter ended June 30, 2026, including net loss of $35.0 million (vs. $17.7 million in Q2 2025), operating expenses of $36.2 million, and cash position of $117.9 million. The press release attached as Exhibit 99.1 presents quarterly financial statements and operating metrics, which is the hallmark of an earnings release under Item 2.02. While the release also includes corporate updates on clinical programs and executive appointments, the primary disclosure is the quarterly financial results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:55:54.506485+00:00","company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","filing_date":"2026-08-06"},{"id":26439,"accession_number":"0001193125-26-336864","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure explicitly references \"Item 2.02 Results of Operations and Financial Condition\" and furnishes Exhibit 99.1, which is a press release titled \"Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update.\" The exhibit contains detailed financial statements (condensed consolidated statements of operations and balance sheets) for the three and six months ended June 30, 2026, showing net loss of $35.0 million for Q2 2026 versus $17.7 million in Q2 2025, along with operating expense details and cash position. This is a standard earnings release disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:55:54.506485+00:00","company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","filing_date":"2026-08-06"}]}